L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for Aptevo Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2025-04-25 4:05 pm Purchase | 2025-04-21 | 13G | Aptevo Therapeutics Inc. APVO | L1 Capital Global Opportunities Master Fund, Ltd. | 21,050 7.590% | 7,200![]() (+51.99%) | Filing |
2025-04-25 4:01 pm Purchase | 2025-04-21 | 13G | Aptevo Therapeutics Inc. APVO | L1 Capital Global Opportunities Master Fund, Ltd. | 13,850 4.990% | 3,850![]() (+38.50%) | Filing |
2025-04-07 4:51 pm Purchase | 2025-04-02 | 13G | Aptevo Therapeutics Inc. APVO | L1 Capital Global Opportunities Master Fund, Ltd. | 10,000 6.210% | 10,000![]() (New Position) | Filing |